AbbVie's long-acting anti-IL-13 antibody zumilokibart – the main asset in its $10.9 billion takeover of Apogee Therapeutics – ...

Two Indian nationals are facing charges relating to the sale of counterfeit versions of Novo's diabetes treatment Ozempic to ...

Eli Lilly's triple G agonist retatrutide has achieved impressive weight loss in patients with type 2 diabetes and obesity, ...

The pharmaceutical industry is undergoing an era of innovation and change. Over the next few years, companies will need to ...

AZ's $2 billion investment – at $18.36 per share – puts the UK-headquartered company in the driving seat to pair its ...

A new event at CPHI Milan 2026 hopes to inspire delegates to collaborate on some of the pharmaceutical industry’s biggest ...

Against this backdrop, the Leadership Summit will return to CPHI Milan in 2026, bringing senior pharmaceutical ...

Sustainability in Life Sciences Summit is the premier meeting point for sustainability, ESG, corporate responsibility, ...

The first product from AbbVie's $8.7 billion takeover of Cerevel two years ago – Parkinson's disease therapy tavapadon – has ...

MSD has signed a global license agreement for a KRAS G12D inhibitor from China's SciBrunch Therapeutics, paying $400 million ...

Patients with fibrodysplasia ossificans progressiva (FOP) in the US will soon have the option of treatment with another daily ...

A team from the Garvan Institute of Medical Research in Darlinghurst, New South Wales, have used an emerging form of genetic ...